Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLOB cells with ceramic scaffold · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALLOB® cells with ceramic scaffold | EXPERIMENTAL | ALLOB® cells with ceramic scaffold Implantation |
| Name | Type | Description |
|---|---|---|
| ALLOB® cells with ceramic scaffold | DRUG | Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia |
Inclusion Criteria: * Ability to provide a written, dated, and signed informed consent prior to any study related procedure, and to understand and comply with study requirements * Symptomatic degenerative disc disease of the lumbar spine requiring a single level lumbar fusion (L1-S1) * Unresponsive...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mesoblast Limited Sponsored ADR | MESO | 1 | PHASE3 | Rexlemestrocel-L |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
ALLOB cells with ceramic scaffold is an investigational biologic product being developed by Bone Biologics Corp (BBLG) for degenerative disc disease. It combines allogeneic osteoblastic cells with a ceramic scaffold and is intended for use in lumbar spinal fusion procedures. The product is in Phase 2 clinical development.
ALLOB cells with ceramic scaffold is being studied for degenerative disc disease, specifically in lumbar spinal fusion. The Phase 2a trial evaluated its use in that indication. It is not approved for any indication and remains investigational.
ALLOB cells with ceramic scaffold is developed by Bone Biologics Corp, which trades under the ticker BBLG. The company is the sponsor of the clinical program for this product.
ALLOB cells with ceramic scaffold is in Phase 2 development. One Phase 2a trial has been completed, and no active trials are currently listed. The product is investigational and has not been approved by the FDA.
ALLOB cells with ceramic scaffold has been studied in one completed Phase 2a trial, NCT02205138, titled Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion. The trial enrolled 38 participants with degenerative disc disease in Belgium and was uncontrolled.